Not medical advice. A record of published research and our assessments of it. The limits

Role of GLP1 RA Dulaglutide on Severe Intracranial Atherosclerosis

Role of Glucagon-like Peptide 1 Receptor Agonist (GLP1 RA) Dulaglutide on Cerebral Hemodynamics In Patients With Severe and symptomAtic steNosis of inTracranial Internal Carotid Artery or Middle Cerebral Artery With Impaired Cerebral Vasodilatory Reserve- an Open-label Randomised Clinical Trial (RADIANT)
NCT07282041 on ClinicalTrials.gov

Status: RecruitingResults none
Why it is watched: non-weight indication: cardiovascular, cerebrovascular
Who it enrolls: age 21 Years to 80 Years; no BMI minimum stated; conditions: Intracranial Atherosclerosis; Stroke, Ischemic
Interventions: Dulaglutide
Conditions: Intracranial Atherosclerosis; Stroke, Ischemic
Phase and size: Phase 2, Phase 3 · 130 participants
Dates: Start 2025-12-17
Primary completion 2030-12-01
Sponsor: National University of Singapore (Other)
Last checked: Sep 13, 2026

01Endpoints

What the trial will measure

To evaluate whether GLP1 RA (Dulaglutide) therapy would improveme cerebral vasodilatory reserve by at least 4 points in patients with severe stenosis of ICA or MCAwithin 1 year

02Eligibility

Who can take part

Inclusion Criteria: * Adult patients aged 21 - 80 years old inclusive, * Able to provide consent, * Score 3 or less on the Modified Rankin Score (mRS), * Patients with TIA or mild stroke with severe stenosis of intracranial ICA or MCA and impaired CVR within previous 3-months of acute stroke or TIA Exclusion Criteria: * Chronic kidney disease stage 5 (eGFR\<15 mL/min) or on dialysis, * Cancer diagnosed within past 3 years, * Currently being planned for coronary or carotid artery revascularization, * History of previous pancreatitis, * History of medullary thyroid cancer, * Atrial fibrillation, * Any other condition likely to limit protocol compliance (judged by investigator). * For diabetic patients, patients should not be on Sodium-glucose cotransporter 2 (SGLT2) inhibitor or pioglitazone during the duration of the study, unless these drugs can be stopped without affecting participants' medical condition. For those on Dipeptidyl peptidase-4 (DPP IV) inhibitor, this agent will be discontinued if the patient is randomised to the intervention group. * Known allergies to Acetazolamide. * Women who are pregnant or breastfeeding.

03Change log

Registry changes

No changes recorded since the trial was added.